- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/14 - Nitrogen atoms
Patent holdings for IPC class C07D 261/14
Total number of patents in this class: 272
10-year publication summary
|
27
|
20
|
11
|
13
|
9
|
9
|
11
|
10
|
12
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Amira Pharmaceuticals, Inc. | 70 |
20 |
| Boehringer Ingelheim International GmbH | 4645 |
16 |
| Bristol-myers Squibb Company | 4872 |
9 |
| Cytokinetics, Inc. | 280 |
8 |
| Epigen Biosciences, Inc. | 13 |
8 |
| Centrexion Therapeutics Corporation | 65 |
7 |
| Vectus Biosystems Limited | 35 |
7 |
| Oryzon Genomics S.A. | 107 |
5 |
| Plexxikon Inc. | 151 |
5 |
| Proteostasis Therapeutics, Inc. | 70 |
5 |
| Autobahn Therapeutics, Inc. | 41 |
5 |
| Novartis AG | 10727 |
4 |
| BASF SE | 20967 |
4 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 545 |
4 |
| Takeda Pharmaceutical Company Limited | 2703 |
4 |
| Chiesi Farmaceutici S.p.A. | 968 |
4 |
| Romark Laboratories L.C. | 52 |
4 |
| Merck Sharp & Dohme LLC | 3748 |
4 |
| Board of Regents, The University of Texas System | 5828 |
3 |
| Northwestern University | 3403 |
3 |
| Other owners | 143 |